Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 15, 2000Cancer

Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II

View Full Paper
Ask AI
Bookmark
Share

Authors

ZKZsuzsanna Kah�nBSBaodong SunOAO VNIPIneft (Russia)
Andrew V. Schally
Andrew V. SchallyUniversity of Miami

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kah�n et al. (2000) studied this question.

synapsesocial.com/papers/6a795ea402ab7a73dd024f8fhttps://doi.org/10.1002/(sici)1097-0142(20000315)88:6<1384::aid-cncr16>3.0.co;2-q
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma1998 · 53 citations
  2. 2In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma1998 · 69 citations
  3. 3Growth Inhibition of Estrogen-Dependent and Estrogen-Independent MXT Mammary Cancers in Mice by the Bombesin and Gastrin-Releasing Peptide Antagonist RC-30951992 · 57 citations
  4. 4Epidermal Growth Factor1979 · 2,939 citations
  5. 5Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II1998 · 35 citations